Efficacy and Failure Patterns of Prophylactic Cranial Irradiation in Patients with Limited-stage Small Cell Lung Cancer Who Were Estimated by Modern Brain Imaging and Treated with Standard Chemoradiotherapy
X. Liu,Z. Zhou,X. Dong,Z. Xiao,Q. Feng,D. Chen,J. Lv,J. Liang,X. Wang,Z. Hui,L. Wang,Y. Li
DOI: https://doi.org/10.1016/j.ijrobp.2019.06.1278
2019-01-01
Abstract:Our study aimed to investigate the clinical efficacy and failure patterns of prophylactic cranial irradiation(PCI) in patients with limited-stage small cell lung cancer (LS-SCLC)who were estimated by modern brain imaging and treated with standard chemoradiotherapy. From August 2006 to May 2014, 385 patients with LS-SCLC were enrolled onto this retrospective study. All patients were primarily managed with concurrent or sequential chemoradiotherapy (≥3 cycles of EP/CE regimens and IMRT), after which patients with no progression and complete or partial response (CR/PR) were treated with PCI (n=159) or observation (n=226). Enhanced computed tomography or magnetic resonance imaging of brain was performed routinely before PCI and during the follow-up period. The overall survival (OS) and cumulative incidence of brain metastasis (BM) were estimated using the Kaplan-Meier method. Log-rank test and Cox regression were used for univariate and multivariate analysis of prognostic factors. The median follow-up time was 33.8 months (6.1-133.3 months). The median survival time (MST), 2-, 3-, and 5-year OS were 57.0 months (95%CI 31.6-82.5 months), 72.3%, 56.6%, and 47.1% in PCI group and 27.9 months (95%CI 23.0-32.8 months), 56.1%, 41.9%, and 28.6% in non-PCI group (HR=0.61, 95%CI 0.48-0.78; P<0.001). Multivariate analysis revealed that smoking history (P=0.021), treatment response (P<0.001) and PCI (P=0.014) were independent prognostic factors of OS. In stratification analysis, PCI significantly improved 5-year OS in patients with CR (67.9% vs. 50.3%, P=0.024) compared with non-PCI group, but nearly improved OS in patients with PR (34.1% vs. 22.6%, P=0.051). The main failure pattern is distant metastasis (49.1%) of all patients, followed by local regional recurrence (26.6%). Most common metastasis site is brain, and 2-, 5-year cumulative rate of BM were 7.5%, 11.9% in PCI group and 29.2%, 30.9% in non-PCI group (P<0.001). The median time and cumulative rate of brain metastasis as an isolated first site of relapse was 15.5 months, 6.9% in PCI group and 9.8 months, 27.0% in non-PCI group (P=0.008). In the new era of more standard chemoradiotherapy and more accurate brain imaging methods, PCI was associated with a significant survival benefit for LS-SCLC patients who had CR to chemoradiotherapy, and prolonged the time to BM, and reduced the cumulative incidence of BM.